Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Conditions: Pancreatic Cancer Interventions: Drug: BNT321 Dose Level 1; Drug: BNT321 Dose Level 2; Drug: mFOLFIRINOX; Drug: BNT321 RP2D Sponsors: BioNTech SE Not yet recruiting

https://clinicaltrials.gov/study/NCT06069778

Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials